Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)

Yamamoto, Tomohisa; Fujii, Tsutomu; Hirano, Satoshi; Motoi, Fuyuhiko; Honda, Goro; Uemura, Kenichiro; Kitayama, Joji; Unno, Michiaki; Kodera, Yasuhiro; Yamaue, Hiroki; Shimokawa, Toshio; Hashimoto, Daisuke; Yamaki, So; Yoshitomi, Hideyuki; Miura, Fumihiko; Ueno, Hideki; Sekimoto, Mitsugu; Satoi, Sohei; behalf of the Study Group of Pancreatic Ductal Adenocarcinoma with Peritoneal Metastasis, on

doi:10.1186/s13063-022-06049-7

Public

Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)

Published in Trials • Feb 5, 2022

Authors:

Tomohisa Yamamoto

Tsutomu Fujii

Satoshi Hirano

Abstract

The prognosis of pancreatic ductal carcinoma (PDAC) with peritoneal metastasis remains dismal. Systemic chemotherapy alone may not be effective, and the combination of intraperitoneal chemotherapy with systemic chemotherapy is expected to prolong the overall survival in patients with peritoneal meta...

Subject

Medicine

Gemcitabine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!